Decoy Therapeutics Inc.
DCOY
$5.15
-$0.29-5.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 402.20K | 833.30K | 849.20K | 1.64M | 1.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 516.60K | 895.10K | 965.60K | 1.72M | 1.99M |
| Operating Income | -516.60K | -895.10K | -965.60K | -1.72M | -1.99M |
| Income Before Tax | -8.98M | -873.50K | -957.80K | -1.71M | -1.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.98M | -873.50K | -957.80K | -1.71M | -1.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.98M | -873.50K | -957.80K | -1.71M | -1.46M |
| EBIT | -516.60K | -895.10K | -965.60K | -1.72M | -1.99M |
| EBITDA | -512.80K | -894.00K | -964.50K | -1.72M | -1.99M |
| EPS Basic | -23.46 | -4.58 | -4.58 | -4.58 | -4.58 |
| Normalized Basic EPS | -0.75 | -- | -- | -- | -3.84 |
| EPS Diluted | -23.46 | -4.58 | -4.58 | -4.58 | -4.58 |
| Normalized Diluted EPS | -0.75 | -- | -- | -- | -3.84 |
| Average Basic Shares Outstanding | 382.70K | -- | -- | -- | 319.60K |
| Average Diluted Shares Outstanding | 382.70K | 319.60K | 319.60K | 319.60K | 319.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |